Aims The mucopolysaccharidoses (MPS) are a heterogeneous group of rare disorders characterised by accumulation of glycosaminoglycans within multiple organ systems. This study aimed to determine the prevalence and severity of ocular complications in patients with MPS. Methods Clinical ophthalmic features and electrodiagnostic results of 50 patients with a diagnosis of MPS were retrospectively reviewed. Results A total of 79% of MPS IH patients had a visual acuity of less than 6/12 equivalent in their better eye, compared to 44% of MPS IH/S and 25% of MPS VI patients. In total, 16% of MPS IH and 25% of MPS IH/S had severe corneal opacification, compared to 38% of MPS VI patients. 16% of MPS IH patients had optic atrophy; 21% of MPS VI patients had mild disc swelling, 29% had markedly swollen discs, and 14% had optic atrophy. One patient with MPS IH, one with MPS IH/S and six with MPS VI had ocular hypertension. One MPS VI patient had glaucoma that required topical therapy. Nine patients with MPS IH had electrodiagnostic evidence of retinopathy, as did one MPS VI patient. Conclusions Ocular complications causing significant reduction in vision are common in MPS. The majority of MPS I and MPS VI patients have corneal opacification, which can lead to difficulties in diagnosis and monitoring of glaucoma, optic disc changes, and retinopathy.
Introduction
The mucopolysaccharidoses (MPS) are a group of disorders characterised by accumulation of glycosaminoglycans (GAG) within a wide variety of tissues, including those of the eye. The MPS have been historically subdivided into different types depending on clinical manifestations and they encompass a wide spectrum of phenotypes, ranging from those disorders, which are fatal in the first months of life to those compatible with a normal lifespan. 1, 2 The MPS result from inherited abnormalities of specific lysosomal enzymes involved in degradation of GAG 3 (Table 1) . Ophthalmic complications are common in MPS, including corneal opacification. This occurs as a result of GAG accumulation both intra-and extracellularly in corneal epithelium, keratocytes, stroma, and endothelium, with subsequent disruption of the optically important arrangement of collagen fibrils. 4, 5 Ocular hypertension and glaucoma occur in MPS due to GAG acumulation within anterior chamber structures. This can lead to narrowing of the anterior chamber angle, 6, 7 and deposition within trabecular cells may lead to obstruction of outflow. 8, 9 Retinopathy occurs as a result of GAG accumulation within retinal pigment epithelial cells and interphotoreceptor matrix, leading to progressive photoreceptor loss. 10 Optic nerve abnormalities are reported to be common in MPS. 11 Optic disc swelling and subsequent optic atrophy occur secondary to raised intraocular pressure (IOP), 12 or as a result of compression of the nerve by GAG in thickened dura and sclera, 11, 13 or accumulation of GAG within ganglion cells. 14 
Mucopolysaccharidoses type I (MPS I) is
caused by abnormalities of the enzyme a-Liduronidase. This manifests as a phenotypic spectrum of skeletal, cardiac, and respiratory problems. 3, 15 MPS IH Hurler syndrome presents with facial dysmorphism and respiratory disease in early life, and patients may be referred to the ophthalmologist once the diagnosis is already made for detection of associated corneal opacification. 15 Retinopathy is a common complication in older children with MPS IH but may be difficult to detect because of corneal opacity. 16 Electroretinography (ERG) usually demonstrates a reduction in dark-adapted b-wave in the early stages. MPS IS Scheie has milder systemic and ophthalmic manifestations, and MPS IH/S Hurler/ Scheie is an intermediate phenotype. 3 Hunter syndrome (MPS II) exhibits a wide variation in clinical severity, with seizures and learning difficulties as common features. 3 MPS III Sanfilippo results from defects in four different enzymes (Table 1) , which result in clinically indistinguishable phenotypes. Patients with MPS III Sanfilippo present with learning difficulties and severe behavioural disturbance, but have mild systemic manifestations. 3 The main feature of MPS IV Morquio is the severe skeletal changes. 17 MaroteauxLamy (MPS VI) results in a spectrum of phenotypic severity, including short stature and variable skeletal deformities. 3 Affected individuals are usually intellectually normal.
The ocular management of many patients with MPS has traditionally been conservative because of their short lifespan and intellectual impairment. However, modern treatments including bone marrow transplantation (BMT) and enzyme replacement therapy (ERT) in MPS I can result in a longer and better quality life for many patients. [18] [19] [20] ERT is currently licensed for use in MPS I (as Laronidase) and is undergoing clinical trials for use in MPS II and VI. ERT improves respiratory function, endurance, joint mobility, growth (in prepubertal patients), and hair and facial appearance in MPS I. 21 The effects of these treatments on the ophthalmic complications of MPS is, at present, unknown. This study aimed to determine the prevalence and severity of ophthalmic complications in patients with MPS seen at the Willink Unit, Royal Manchester Children's Hospital, and Manchester Royal Eye Hospital.
Methods
We retrospectively reviewed the notes of patients seen in the Manchester Royal Eye Hospital paediatric ophthalmology clinic from 1996 to 2003 with a diagnosis of MPS. The patients were identified from the paediatric ophthalmology diagnostic database. The age of the patient at most recent examination was documented, as well as the visual acuity, presence of strabismus, refractive error, and IOP measurement if possible (performed by noncontact air-puff tonometry in the clinic). The degree of corneal opacification was subjectively graded (by a single observer, ICL) as mild ( þ ), moderate ( þ þ ), or severe ( þ þ þ ). The appearance of the optic disc, if visualisation was possible, was noted as normal, atrophic, swollen, or cupped. The presence of retinopathy was determined by dilated fundal examination of the retina and by electroretinography (ERG). Visual evoked potentials (VEPs) were performed in cases of suspected optic nerve dysfunction.
Results
A total of 50 patients were identified with a diagnosis of MPS. Among them, 19 patients had MPS IH Hurler, nine had MPS IH/S Hurler/Scheie, and three had MPS IS Scheie. There were two patients with MPS II Hunter and one patient had MPS III Sanfilippo. There were 16 patients with MPS VI Maroteaux-Lamy.
The age range of the patients with MPS IH was 4 months to 23 years, with a mean of 6 years and 2 months. The age range of the MPS IH/S patients was 2-22 years and the mean was 12 years 9 months. The range of the MPS IS patients was 7-16 years and the mean was 11 Table 2 ) to cortical visual impairment, and to optic atrophy secondary to previous raised intracranial pressure in another (patient 13H, Table 2 ). Six out of 19 (32%) of MPS IH patients had amblyopia, compared to three out of nine (33%) patients with MPS IH/S. All three patients with MPS IS Scheie had vision better than 6/12 in at least one eye, and only one had amblyopia. Both MPS II Hunter patients had 6/6 vision or better in both eyes and neither had amblyopia. The MPS III patient had severe learning difficulties, and his vision was measured at 6/38 with Cardiff cards. Four out of 16 (25%) of patients with MPS VI Maroteaux-Lamy had vision less than 6/12 in the better eye. Two (13%) MPS VI patients had vision 3/60 or less in their better eye, and both these patients both had optic atrophy secondary to previous raised intracranial pressure (patients 3VI and 16VI, Table 7 ). Seven out of 16 (44%) MPS VI patients had amblyopia.
All MPS I patients had some degree of corneal opacification (Graph 1), although one patient with MPS IH/S had previously undergone penetrating keratoplasty with a centrally clear donor cornea in both eyes at 3 and 6 years follow-up (patient 4H/S, Table 3 ). Nine out of 19 (47%) patients with MPS IH Hurler had mild corneal opacification (Figure 1 ), seven out of 19 (37%) had moderate opacification, and three out of 19 (16%) had severe corneal opacification. Three out of eight (38%) patients with MPS IH/S Hurler/Scheie had mild corneal opacification, three (38%) had moderate, and two (25%) had severe opacification. Two out of three (66%) MPS IS Scheie patients had mild opacification and one had moderate opacification (Table 4 ). All MPS II Hunter and MPS III Sanfilippo patients had clear corneas (Tables 5   and 6 ). Five out of 16 (31%) MPS VI Maroteaux-Lamy patients had mild corneal opacity, four (25%) had moderate, and six (38%) severe ( Figure 2 ). One MPS VI patient with severe corneal opacification had undergone successful penetrating keratoplasty in one eye with maintenance of a clear donor cornea at 5 years, but had limitation of vision due to optic atrophy (patient 3VI, Table 7 ).
In total, 16 (84%) MPS IH Hurler patients had normal optic discs and three (16%) had optic atrophy (Graph 2). Only one (11%) of the MPS IH/S patients had disc swelling and the other eight patients all had normal discs. All three MPS IS Scheie patients had healthy discs. Both patients with MPS II Hunter had mild disc swelling, and the patient with MPS III Sanfilippo had temporal optic atrophy. Four out of 14 (29%) MPS VI MaroteauxLamy patients had normal discs, three (21%) had mild disc swelling, four (29%) had markedly swollen discs, two (14%) had optic atrophy ( Figure 3 ), and one (7%) had a cupped disc due to raised IOP. The view of the optic disc was obscured by marked corneal opacification in two patients with MPS VI.
The incidence of ocular hypertension and glaucoma in the MPS patients was low (Graph 3). Only one patient with MPS IH Hurler had ocular hypertension with IOPs of 22 mmHg right and 25 mmHg left eye, and normal optic discs. All other MPS IH patients (95%) had IOPs less than 21 mmHg. One patient with MPS IH/S had IOPs of 31 mmHg right and 33 mmHg left with normal optic discs. All MPS IS Scheie and MPS III Sanfilippo patients had IOPs less than 21 mmHg. IOP measurements were not available for the MPS II Hunter patients. In total, 13 patients with MPS VI had IOP measurements documented. Of these, five (38%) had IOPs greater than 21 mmHg and a further two had IOPs greater than 30 mmHg (15%). One of these had IOPs of 33 mmHg in both eyes, marked corneal opacification and a cup : disc ratio of 0.7 both eyes. This patient (4VI, Table 7 ) was started on topical antihypertensive medication (latanoprost).
IOP was higher in the patients with more severe corneal opacification (Graph 4). The mean IOP in MPS I patients with mild corneal opacification was 13.2374.75 mmHg. The mean IOP was 17.0073.98 mmHg in those MPS I patients with moderate corneal opacification and 19.4077.19 mmHg in those with severe corneal opacification (ANOVA analysis, P ¼ 0.03). As a statistically significant difference between the three groups was found, a Tukey multiple comparison test was carried out. This showed that IOP in the mild corneal opacification group was significantly different from both the moderate and severe groups, while there was no significant difference between the moderate and severe corneal opacification groups. In the 
8 m Roving eye movements and nystagmus (Figure 4) , and two (66%) patients with MPS IS Scheie. All MPS II Hunter and MPS III Sanfilippo patients had clinically normal fundii. There were three MPS VI Maroteaux-Lamy patients in whom it was impossible to get a clear fundal view due to the marked corneal opacification, but all of those fundii visualised were clinically normal.
A total of 13 patients with MPS IH Hurler had undergone ERGs. Nine (69%) of these had reduced b-waves in dark-adapted conditions, and one of these had reduced b-waves when light adapted also. Only one patient with MPS IH/S Hurler/Scheie had an ERG performed, which showed reduced b-waves on dark adaptation. Electroretinography was not available on any patients with MPS IS Scheie or MPS II Hunter. The MPS III Sanfilippo patient demonstrated reduced amplitude of their dark-adapted ERG. Eight patients with MPS VI Maroteaux-Lamy underwent ERGs, and one (12%) had a reduced dark-adapted amplitude Table 2 ) developed bilateral posterior subcapsular cataracts. These patients had both undergone two previous bone marrow transplants. Eight MPS IH patients were examined after undergoing bone marrow transplant with a follow-up of 1 month-9 years, and Figure 2 Severe corneal opacification in a 16-year-old patient with MPS VI Maroteaux-Lamy. 
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Eye mean follow-up of 5 years 5 months. The age range of these patients was 15 months-23 years, with a mean of 8 years 5 months. Two of these patients (25%) had mild corneal opacification, five (62.5%) had moderate, and one (12.5%) marked opacification. Six (75%) of these patients had visual acuities less than 6/12 Snellen equivalent in the better eye.
Discussion
This is the first large case series to comprehensively describe the ophthalmic features seen in patients with MPS. This study demonstrates that corneal opacification is a common feature in all MPS I subgroups (Hurler, Hurler/Scheie, and Scheie) and also in MPS VI Maroteaux-Lamy. [22] [23] [24] [25] [26] [27] [28] Our results suggest that corneal opacification tends to be more severe in MPS VI Maroteaux-Lamy than MPS I subgroups. We have confirmed that corneal opacity is not a prominent feature in MPS II or MPS III. 24, 29 Retinopathy is known to occur to a variable degree in all MPS I subgroups, MPS II Hunter and moderate or severe retinopathy is a common feature of MPS III Sanfilippo. 16, 30, 31 Pigmentary retinopathy may also occur in MPS IV Morquio. 32 We have electrodiagnostic evidence of retinopathy in a high proportion (69% of those who had ERGs performed) of MPS I Hurler patients, and clinical retinal pigment epithelial changes suggestive of retinopathy in a significant proportion of MPS IH/S Hurler/Scheie (56%) and MPS IS Scheie patients (66%). In keeping with other reports, the patient with MPS III Sanfilippo had ERG evidence of retinopathy consistent with their reduced visual acuity. Retinopathy has not previously been reported in MPS VI, but we found one patient with ERG attenuation despite normal acuity and a normal retinal examination, suggesting that retinopathy may be an additional feature in some cases of MPS VI Maroteaux-Lamy. The incidence of optic disc swelling in MPS I was much lower than reported in previous studies. Collins et al 11 described optic disc abnormalities in a series of 108 MPS patients and found that 57% of patients with MPS IH Hurlers and 43% of MPS IH/S Hurler/Scheie patients had optic disc swelling. None of the MPS IH patients and only one patient with MPS IH/S had disc swelling in the current study. Our figures may perhaps be attributed to better recognition and management of raised intracranial pressure in this group of patients. Our findings in the MPS VI Maroteaux-Lamy patients were similar to those of Collins, who found 41% to have optic disc swelling and 8% atrophy. 11 Optic atrophy occurred secondary to previous episodes of raised intracranial pressure in three out of six patients in this study. Visual loss was profound (to perception of light level only) in these patients, suggesting that raised intracranial pressure and subsequent optic atrophy is a significant cause of severe visual loss in MPS patients.
There have been no previous studies of the incidence of ocular hypertension or glaucoma in MPS patients. Previous case reports have described open angle glaucoma in MPS IH, 9, 33, 34 MPS IH/S, 35 and MPS VI. 36 Angle closure glaucoma has been reported in MPS IS Scheie, 37 MPS IH/S, 38 MPS II Hunter, 39 and MPS VI Maroteaux-Lamy. 36 In our study, there was a low incidence of ocular hypertension and glaucoma in all MPS I subgroups, with only one MPS IH Hurler patient and one MPS IH/S Hurler/Scheie patient having raised IOP. Ocular hypertension was more common in the MPS VI Maroteaux-Lamy patients, with 38% having IOP greater than 21 mmHg and a further 15% having IOP greater than 30 mmHg, perhaps due to the more marked corneal changes in these patients. Only one MPS patient required topical glaucoma medication, and there were no cases of acute glaucoma in our series. However, the incidence of open angle glaucoma could be expected to increase with age.
Diagnosis and monitoring of ocular hypertension and glaucoma is often difficult in patients with MPS due to their multiple physical and intellectual difficulties hampering assessment of IOP and visual fields. In addition, the presence of corneal opacity may cause difficulties in visualisation of the optic disc, and assessment of disc cupping may also be made more difficult due to coexistent disc abnormalities. Corneal thickening due to GAG deposition may also lead to falsely high IOP readings. We found a statistically significant relationship between IOP and degree of corneal opacification in MPS I and MPS VI patients. Future studies are needed to assess the correlation between corneal opacification, corneal thickness, and IOP readings in MPS patients.
This study demonstrates that visual impairment is common in MPS patients, and that a significant proportion of both MPS I Hurler (11%) and MPS VI Maroteaux-Lamy (13%) patients have marked visual impairment with a Snellen acuity of 3/60 or less in their better eye. Optic atrophy secondary to raised intracranial pressure was the cause of severe visual impairment in three of the four patients in this study with vision 3/60 or less, highlighting the importance of early diagnosis and monitoring of raised intracranial pressure in these patients. The overall incidence of visual impairment (measured as vision worse than 6/12 Snellen equivalent in the better eye) was higher in the MPS IH Hurler (79%) and MPS IH/S Hurler/Scheie (44%) than in the MPS VI patients (25%), despite the more marked corneal opacification and higher incidence of optic nerve involvement in the MPS VI patients. This may perhaps reflect the low incidence of retinopathy in MPS VI, or be attributed to nonocular causes of visual impairment in MPS I patients such as cortical visual impairment. This study demonstrates that mild corneal opacity is compatible with excellent Snellen acuity, although patients may experience glare and reduced contrast sensitivity, visual modalities not assessed here. Refractive error, which occurs due to refractive changes in the cornea, 40 squint and amblyopia were all common in this series of MPS patients.
Previous studies have suggested a possible beneficial effect of BMT on the ocular manifestations of MPS. 41, 42 Summers et al 41 prospectively followed 11 patients after BMT for up to 2.8 years and found evidence of clearing of corneal opacification, resolution of optic nerve oedema, and stabilised or improved retinal function. Gullingsrud et al found in a retrospective study that six out of 20 patients had clinical improvement in corneal clouding and five patients had increase in clouding at 7-24 months after BMT. In total, 81% of patients had improvement in ERG in the first year, followed by a slowly progressive deterioration in all patients over a further 5 years. 42 Our study has not analysed the effect of BMT on the ophthalmic complications, but there was still a significant proportion (75%) of MPS IH patients with viusal impairment who had undergone previous BMT. The effects of ERT, and combined early treatment with BMT and ERT, on the ocular manifestations of MPS are not yet defined, and further studies are needed to determine whether ocular complications are stabilised or improved by these treatments.
Patients with MPS require regular ophthalmic assessment to detect, monitor, and treating ocular complications. The profound effect of poor vision on a young patient, who may also be suffering multiple physical and intellectual problems, means that the ocular management of these patients is a crucial part of their multidisciplinary care. In addition, the ophthalmologist may pick up signs of raised intracranial pressure, which as this study demonstrates is a major cause of visual impairment.
